Itamar Medical Ltd. | Income Statement

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
48,140.00
58,619.50
65,298.90
70,786.80
74,461.00
86,965.80
Cost of Goods Sold (COGS) incl. D&A
15,874.60
17,510.40
18,004.10
20,303.20
19,139.50
21,399
Gross Income
32,265.40
41,109.10
47,294.80
50,483.60
55,321.50
65,566.80
SG&A Expense
44,711.00
53,164.30
67,750.50
87,735.00
75,572.40
76,787.60
EBIT
12,687.40
12,266.20
20,455.70
37,251.40
20,251.00
11,220.80
Unusual Expense
18,199.10
12,745.50
30,056.10
2,011.50
13,334.00
8,747.30
Non Operating Income/Expense
1,126.20
3,602.20
2,824.60
783.10
618.70
28.80
Interest Expense
17,769.60
8,148.80
14,981.40
18,406.90
17,459.70
4,145.30
Pretax Income
46,790.10
11,271.70
8,205.60
54,786.90
18,761.80
5,770.40
Income Tax
158.80
443.60
524.50
502.90
305.70
445.80
Consolidated Net Income
46,631.20
11,715.30
8,730.10
55,289.70
19,067.60
6,216.20
Net Income
46,631.20
11,715.30
8,730.10
55,289.70
19,067.60
6,216.20
Net Income After Extraordinaries
46,631.20
11,715.30
8,730.10
55,289.70
19,067.60
6,216.20
Net Income Available to Common
46,631.20
11,715.30
8,730.10
55,289.70
19,067.60
6,216.20
EPS (Basic)
0.32
0.07
0.04
0.19
0.07
0.02
Basic Shares Outstanding
138,555.50
176,362.20
191,809.00
262,543.00
264,109.00
277,665
EPS (Diluted)
0.34
0.08
0.07
0.21
0.08
0.05
Diluted Shares Outstanding
138,555.50
216,422.20
231,884.00
262,543.00
303,986.00
320,911
EBITDA
11,572.10
11,107.20
19,029.80
35,585.40
18,420.10
9,491.50
Other Operating Expense
241.80
211.10
-
-
-
-
Non-Operating Interest Income
2,992.30
-
-
2,099.80
4,996.20
877.20

About Itamar Medical

View Profile
Address
9 Halamish Street
Caesarea HA 38900
Israel
Employees -
Website http://www.itamar-medical.com
Updated 07/08/2019
Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. The firm develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease.